Literature DB >> 15788786

Biochip for K-ras mutation screening in ovarian cancer.

Gerhild Fabjani1, Gernot Kriegshaeuser, Andreas Schuetz, Lothar Prix, Robert Zeillinger.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15788786     DOI： 10.1373/clinchem.2004.041194

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  4 in total

1.  Biochip-based detection of KRAS mutation in non-small cell lung cancer.

Authors:  Gernot Kriegshäuser; Gerhild Fabjani; Barbara Ziegler; Sabine Zöchbauer-Müller; Adelheid End; Robert Zeillinger
Journal:  Int J Mol Sci       Date:  2011-11-29       Impact factor: 5.923

2.  Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Authors:  Björn Nodin; Nooreldin Zendehrokh; Magnus Sundström; Karin Jirström
Journal:  Diagn Pathol       Date:  2013-06-25       Impact factor: 2.644

3.  Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.

Authors:  Yi-Ju Lee; Ming-Yung Lee; Alexandra Ruan; Chi-Kuan Chen; Hao-Ping Liu; Chau-Jong Wang; Wan-Ru Chao; Chih-Ping Han
Journal:  Oncotarget       Date:  2016-12-13

4.  KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

Authors:  Veronika Auner; Gernot Kriegshäuser; Dan Tong; Reinhard Horvat; Alexander Reinthaller; Alexander Mustea; Robert Zeillinger
Journal:  BMC Cancer       Date:  2009-04-09       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.